S&P 500   4,406.51 (+1.30%)
DOW   34,669.27 (+1.47%)
QQQ   348.70 (+1.20%)
AAPL   162.89 (+2.00%)
MSFT   305.31 (+2.90%)
FB   301.22 (+2.24%)
GOOGL   2,637.95 (+2.06%)
AMZN   2,865.32 (+3.16%)
TSLA   870.01 (-7.19%)
NVDA   224.08 (-1.60%)
BABA   114.36 (+0.87%)
NIO   21.95 (-3.13%)
AMD   106.76 (-3.57%)
CGC   7.04 (-2.63%)
MU   81.03 (-1.15%)
GE   90.31 (+1.11%)
T   24.27 (+0.08%)
F   19.98 (+0.35%)
DIS   137.77 (+3.12%)
AMC   15.33 (-3.83%)
PFE   54.18 (+2.21%)
ACB   3.92 (-3.45%)
BA   195.19 (+0.47%)
S&P 500   4,406.51 (+1.30%)
DOW   34,669.27 (+1.47%)
QQQ   348.70 (+1.20%)
AAPL   162.89 (+2.00%)
MSFT   305.31 (+2.90%)
FB   301.22 (+2.24%)
GOOGL   2,637.95 (+2.06%)
AMZN   2,865.32 (+3.16%)
TSLA   870.01 (-7.19%)
NVDA   224.08 (-1.60%)
BABA   114.36 (+0.87%)
NIO   21.95 (-3.13%)
AMD   106.76 (-3.57%)
CGC   7.04 (-2.63%)
MU   81.03 (-1.15%)
GE   90.31 (+1.11%)
T   24.27 (+0.08%)
F   19.98 (+0.35%)
DIS   137.77 (+3.12%)
AMC   15.33 (-3.83%)
PFE   54.18 (+2.21%)
ACB   3.92 (-3.45%)
BA   195.19 (+0.47%)
S&P 500   4,406.51 (+1.30%)
DOW   34,669.27 (+1.47%)
QQQ   348.70 (+1.20%)
AAPL   162.89 (+2.00%)
MSFT   305.31 (+2.90%)
FB   301.22 (+2.24%)
GOOGL   2,637.95 (+2.06%)
AMZN   2,865.32 (+3.16%)
TSLA   870.01 (-7.19%)
NVDA   224.08 (-1.60%)
BABA   114.36 (+0.87%)
NIO   21.95 (-3.13%)
AMD   106.76 (-3.57%)
CGC   7.04 (-2.63%)
MU   81.03 (-1.15%)
GE   90.31 (+1.11%)
T   24.27 (+0.08%)
F   19.98 (+0.35%)
DIS   137.77 (+3.12%)
AMC   15.33 (-3.83%)
PFE   54.18 (+2.21%)
ACB   3.92 (-3.45%)
BA   195.19 (+0.47%)
S&P 500   4,406.51 (+1.30%)
DOW   34,669.27 (+1.47%)
QQQ   348.70 (+1.20%)
AAPL   162.89 (+2.00%)
MSFT   305.31 (+2.90%)
FB   301.22 (+2.24%)
GOOGL   2,637.95 (+2.06%)
AMZN   2,865.32 (+3.16%)
TSLA   870.01 (-7.19%)
NVDA   224.08 (-1.60%)
BABA   114.36 (+0.87%)
NIO   21.95 (-3.13%)
AMD   106.76 (-3.57%)
CGC   7.04 (-2.63%)
MU   81.03 (-1.15%)
GE   90.31 (+1.11%)
T   24.27 (+0.08%)
F   19.98 (+0.35%)
DIS   137.77 (+3.12%)
AMC   15.33 (-3.83%)
PFE   54.18 (+2.21%)
ACB   3.92 (-3.45%)
BA   195.19 (+0.47%)

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. BCYP,CASI,ARMP,BCLI,CRXT).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRXT
Clarus Therapeutics
$1.27
-5.2%
$3.31
$1.16
$31.24
$27.59MN/A517,256 shs400 shs
BCLI
Brainstorm Cell Therapeutics
$2.92
-4.6%
$3.53
$2.75
$8.14
$105.93M-0.09134,132 shs488 shs
CASI
CASI Pharmaceuticals
$0.62
+0.2%
$0.81
$0.60
$3.70
$86.31M0.34997,950 shs6,458 shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
CRXT
Clarus Therapeutics
2.28 of 5 Stars
3.55.00.01.71.3
BCLI
Brainstorm Cell Therapeutics
1.97 of 5 Stars
3.34.90.01.70.0
CASI
CASI Pharmaceuticals
2.66 of 5 Stars
3.54.40.04.21.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRXT
Clarus Therapeutics
3.00
Buy$13.40955.12% Upside
BCLI
Brainstorm Cell Therapeutics
2.50
Buy$12.00310.96% Upside
CASI
CASI Pharmaceuticals
3.00
Buy$3.93537.08% Upside

Current Analyst Ratings

Latest BCYP, CASI, ARMP, BCLI, and CRXT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
12/22/2021
BCLI
Brainstorm Cell Therapeutics
Dawson James
Reiterated RatingNeutral
11/15/2021
CASI
CASI Pharmaceuticals
HC Wainwright
Reiterated RatingBuy$4.00
(Data available from 1/27/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRXT
Clarus Therapeutics
N/AN/AN/AN/A$2.35 per shareN/A
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A$1.12 per shareN/A
CASI
CASI Pharmaceuticals
$15.14M5.70N/AN/A$0.66 per share0.94

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRXT
Clarus Therapeutics
-$4.72MN/A0.00N/AN/AN/AN/AN/A2/17/2022 (Estimated)
BCLI
Brainstorm Cell Therapeutics
-$31.81M-$0.88N/AN/AN/AN/A-94.92%-68.14%2/3/2022 (Estimated)
CASI
CASI Pharmaceuticals
-$48.29M-$0.35N/AN/AN/A-175.18%-49.87%-32.52%3/29/2022 (Estimated)

Latest BCYP, CASI, ARMP, BCLI, and CRXT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/20219/30/2021
CRXT
Clarus Therapeutics
-$0.81-$0.26+$0.55-$0.80$3.30 million$4.29 million  
11/15/20219/30/2021
BCLI
Brainstorm Cell Therapeutics
-$0.21-$0.15+$0.06-$0.15N/AN/A    
11/12/20219/30/2021
CASI
CASI Pharmaceuticals
-$0.06-$0.07-$0.01-$0.07$7.77 million$8.11 million    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRXT
Clarus Therapeutics
N/AN/AN/AN/AN/A
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRXT
Clarus Therapeutics
N/A
0.70
0.51
BCLI
Brainstorm Cell Therapeutics
N/A
4.78
4.78
CASI
CASI Pharmaceuticals
N/A
7.23
7.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CRXT
Clarus Therapeutics
81.68%
BCLI
Brainstorm Cell Therapeutics
14.15%
CASI
CASI Pharmaceuticals
46.25%

Insider Ownership

CompanyInsider Ownership
CRXT
Clarus Therapeutics
N/A
BCLI
Brainstorm Cell Therapeutics
21.04%
CASI
CASI Pharmaceuticals
24.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CRXT
Clarus Therapeutics
221.73 millionN/ANot Optionable
BCLI
Brainstorm Cell Therapeutics
4036.28 million28.65 millionOptionable
CASI
CASI Pharmaceuticals
144139.80 million105.80 millionNot Optionable

BCYP, CASI, ARMP, BCLI, and CRXT Headlines

SourceHeadline
FDA grants orphan drug designation to CAR T-cell therapy for advanced ALLFDA grants orphan drug designation to CAR T-cell therapy for advanced ALL
healio.com - January 21 at 3:44 PM
New Orphan Drug Designation for Treatment of Follicular LymphomaNew Orphan Drug Designation for Treatment of Follicular Lymphoma
eturbonews.com - January 20 at 11:42 PM
Casi Pharma-Partnered BioInvents Lead Cancer Program Gets FDA Orphan Drug TagCasi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag
finance.yahoo.com - January 20 at 1:42 PM
CASI Pharma: Bi-1206 Granted Orphan Drug Designation By FDA For Follicular Lymphoma TreatmentCASI Pharma: Bi-1206 Granted Orphan Drug Designation By FDA For Follicular Lymphoma Treatment
markets.businessinsider.com - January 20 at 8:14 AM
CASI announces FDA’s Orphan Drug Designation for follicular lymphoma candidateCASI announces FDA’s Orphan Drug Designation for follicular lymphoma candidate
seekingalpha.com - January 20 at 8:14 AM
$9.06 Million in Sales Expected for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) This Quarter$9.06 Million in Sales Expected for CASI Pharmaceuticals, Inc. (NASDAQ:CASI) This Quarter
americanbankingnews.com - January 19 at 3:42 AM
CASIs partner Juventas CNCT19 for blood cancer gets FDA orphan drug statusCASI's partner Juventas' CNCT19 for blood cancer gets FDA orphan drug status
seekingalpha.com - January 18 at 11:06 AM
CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDACASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA
finance.yahoo.com - January 18 at 11:06 AM
CASI Pharmaceuticals (NASDAQ:CASI) Upgraded by Zacks Investment Research to "Hold"CASI Pharmaceuticals (NASDAQ:CASI) Upgraded by Zacks Investment Research to "Hold"
marketbeat.com - January 17 at 6:50 PM
How Many CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Do Institutions Own?How Many CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Do Institutions Own?
finance.yahoo.com - January 9 at 10:01 AM
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Down 27.5% in DecemberCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Down 27.5% in December
americanbankingnews.com - January 8 at 9:58 AM
Rockville biopharma faces delisting threat from NasdaqRockville biopharma faces delisting threat from Nasdaq
bizjournals.com - January 3 at 2:55 PM
CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE - Form 8-KCASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE - Form 8-K
publicnow.com - January 3 at 9:54 AM
CASI Pharmaceuticals Inc. (NASDAQ: CASI) Have Dipped -72.88% YTD, Predicting What Happens Next InCASI Pharmaceuticals Inc. (NASDAQ: CASI) Have Dipped -72.88% YTD, Predicting What Happens Next In
marketingsentinel.com - January 1 at 10:12 AM
Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) Stock Sentiment: What’s Wall Street Saying?Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) Stock Sentiment: What’s Wall Street Saying?
stocksregister.com - December 28 at 12:40 PM
CASI Pharmaceuticals EPS Diluted (5 Year Growth)CASI Pharmaceuticals EPS Diluted (5 Year Growth)
ycharts.com - December 26 at 10:46 PM
CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAMCASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM
finance.yahoo.com - December 17 at 8:54 AM
CASI Pharmaceuticals Inc. (NASDAQ: CASI) Has Outstanding PotentialCASI Pharmaceuticals Inc. (NASDAQ: CASI) Has Outstanding Potential
stocksregister.com - December 16 at 9:30 AM
CASI Pharmaceuticals, BioInvent Gain CTA Approval for BI-1206CASI Pharmaceuticals, BioInvent Gain CTA Approval for BI-1206
contractpharma.com - December 10 at 2:23 PM
Things To Consider When Buying CASI Pharmaceuticals Inc. (NASDAQ:CASI) SharesThings To Consider When Buying CASI Pharmaceuticals Inc. (NASDAQ:CASI) Shares
stocksregister.com - December 10 at 2:23 PM
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical ...BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical ...
pr-inside.com - December 10 at 8:18 AM
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINACASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA
finance.yahoo.com - December 10 at 8:18 AM
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in ChinaBioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
finance.yahoo.com - December 10 at 8:18 AM
When Will CASI Pharmaceuticals Inc. (CASI) Be Worth Investing In?When Will CASI Pharmaceuticals Inc. (CASI) Be Worth Investing In?
marketingsentinel.com - December 1 at 1:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.